Quick Answer
ZEVRA THERAPEUTICS, INC. reported Operating Income Loss of -$62.94 million for the year ending 2025.
- ZEVRA THERAPEUTICS, INC. showed an increase of +27.7% in Operating Income Loss from 2024 to 2025.
- This data is from ZEVRA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), ZEVRA THERAPEUTICS, INC.'s Operating Income Loss has declined by 1,234.1%.
- Historical annual values: Fiscal year 2025: -$62.94 million | Fiscal year 2024: -$87.00 million | Fiscal year 2023: -$49.60 million | Fiscal year 2022: -$42.57 million | Fiscal year 2021: $7.73 million | Fiscal year 2020: -$5.61 million | Fiscal year 2019: -$20.34 million | Fiscal year 2018: -$55.90 million | Fiscal year 2017: -$33.37 million | Fiscal year 2016: -$37.48 million | Fiscal year 2015: -$22.81 million | Fiscal year 2014: -$16.44 million | Fiscal year 2013: -$4.72 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: